

AXL Kinase Inhibitor - Pipeline Insight, 2022

<https://marketpublishers.com/r/AAE899D8E1B8EN.html>

Date: January 2022

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: AAE899D8E1B8EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "AXL Kinase Inhibitor - Pipeline Insight, 2022" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

AXL Kinase Inhibitor Understanding

AXL Kinase Inhibitor: Overview

Axl receptor tyrosine Kinase is a member of the tyrosine?protein Kinase receptor Tyro3, Axl and proto?oncogene tyrosine?protein Kinase Mer family of receptor tyrosine Kinases. AXL is a member of a complex signaling network that is involved in the control of cell proliferation and differentiation. AXL is widely expressed in healthy tissues, where it plays a variety of roles, including clearing apoptotic material, regulating cell survival, maintaining vascular integrity, and hematopoiesis. AXL has emerged as a novel biomarker due to its role in biological processes and tumorigenesis. Because of the pleiotropic role of AXL in tumor pathophysiology and drug resistance, AXL represents a promising therapeutic target in the management of cancer. AXL inhibitors have been shown to potentiate tumor cell apoptosis and suppress migration and invasion.

Targeting AXL enhances the therapeutic efficacy of chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase Inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase Inhibitor.

AXL Kinase Inhibitor Emerging Drugs Chapters

This segment of the AXL Kinase Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

AXL Kinase Inhibitor Emerging Drugs

Bemcentinib: BerGenBio / Rigel Pharmaceuticals

Bemcentinib (BGB324) is a potent, selective and orally bioavailable AXL inhibitor and a potential future cornerstone to therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. The drug is in phase II program, focused on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy.

Sitravatinib: Mirati Therapeutics

Sitravatinib is an oral, potent, spectrum-selective RTK inhibitor. It inhibits several closely related RTKs, including the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT. This inhibition weakens the cancer's defenses in the tumor microenvironment.

Further product details are provided in the report.....

AXL Kinase Inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different AXL Kinase Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on AXL Kinase Inhibitor

There are approx. 15+ key companies which are developing the AXL Kinase Inhibitor. The companies which have their AXL Kinase Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics.

Phases

DelveInsight's report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III and

Mid-stage products (Phase II and

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

AXL Kinase Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

AXL Kinase Inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase Inhibitor drugs.

AXL Kinase Inhibitor Report Insights

AXL Kinase Inhibitor Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

AXL Kinase Inhibitor Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing AXL Kinase Inhibitor drugs?

How many AXL Kinase Inhibitor drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for AXL Kinase Inhibitor?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the AXL Kinase Inhibitor therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for AXL Kinase Inhibitor and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

BerGenBio

Rigel Pharmaceuticals

Mirati Therapeutics

Ipsen

SignalChem Lifesciences

Arcus Biosciences

Symphogen

Qurient Co

Daiichi Sankyo Company

Aravive

Exelixis

Key Products

Bemcentinib

Sitravatinib

Cabozantinib

Research programme: TAM inhibitors

Research programme: AXL receptor tyrosine kinase inhibitors

Sym 028

Q-702

AB 329

Aravive S6

XL092

Contents

Introduction

Executive Summary

AXL Kinase Inhibitor: Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

AXL Kinase Inhibitor – DelveInsight's Analytical Perspective

In-depth Commercial Assessment

AXL Kinase Inhibitor companies' collaborations, Licensing, Acquisition -Deal Value

Trends

AXL Kinase Inhibitor Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

Sitravatinib: Mirati Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Bemcentinib: BerGenBio/Rigel Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

AB 329: Daiichi Sankyo Company

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Pre-clinical and Discovery Stage Products

Comparative Analysis

Q-702: Qurient Co

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

Comparative Analysis

AXL Kinase Inhibitor Key Companies

AXL Kinase Inhibitor Key Products

AXL Kinase Inhibitor- Unmet Needs

AXL Kinase Inhibitor- Market Drivers and Barriers

AXL Kinase Inhibitor- Future Perspectives and Conclusion

AXL Kinase Inhibitor Analyst Views

AXL Kinase Inhibitor Key Companies

Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for AXL Kinase Inhibitor

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for AXL Kinase Inhibitor

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: AXL Kinase Inhibitor - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/AAE899D8E1B8EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AAE899D8E1B8EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970